Home  /  Resource Library  /  Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL

Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL

For patients who discontinued IB due to non-infectious IB-attributable AEs, subsequent treatment with an alternative BTK inhibitor does not appear to aggravate or precipitate IB-attributable AEs that had previously resulted in discontinuation.